These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2510972)

  • 21. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection.
    Hirao Y; Homma JY
    Jpn J Exp Med; 1978 Feb; 48(1):41-51. PubMed ID: 97424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats.
    Chhibber S; Rani M; Vanashree Y
    Indian J Exp Biol; 2005 Jan; 43(1):40-5. PubMed ID: 15691064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Fürer E
    Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Furer E; Sadoff JC; Germanier R
    Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children.
    CMAJ; 1993 Jan; 148(2):199-214. PubMed ID: 8452591
    [No Abstract]   [Full Text] [Related]  

  • 31. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
    Lieberman MM; Ayala E
    J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
    [No Abstract]   [Full Text] [Related]  

  • 32. Qualitative analysis of antibody binding. An in vitro assay for the evaluation and development of vaccines.
    Bruderer U; Fürer E; Cryz SJ; Lang AB
    J Immunol Methods; 1990 Oct; 133(2):263-8. PubMed ID: 2121830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sporozoite immunity and vaccine development.
    Hockmeyer WT; Ballou WR
    Prog Allergy; 1988; 41():1-14. PubMed ID: 3043419
    [No Abstract]   [Full Text] [Related]  

  • 34. Synthetic peptide vaccine development: measurement of polyclonal antibody affinity and cross-reactivity using a new peptide capture and release system for surface plasmon resonance spectroscopy.
    Cachia PJ; Kao DJ; Hodges RS
    J Mol Recognit; 2004; 17(6):540-57. PubMed ID: 15386623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenic properties of the liposomal form of Pseudomonas aeruginosa anatoxin].
    Minukhin VV; Brodinova NS; Tsyganenko AIa; Ivanova NN; Vasil'chenko VN; Sennikov GA
    Vestn Akad Med Nauk SSSR; 1990; (8):44-7. PubMed ID: 2125778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial toxin vaccines.
    McDonel JL
    Adv Biotechnol Processes; 1990; 13():1-33. PubMed ID: 2110461
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.
    Lang AB; Horn MP; Imboden MA; Zuercher AW
    Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.